| 章斌,焦秀秀,沈波,李艳.PD-1/PD-L1抗体类药物致免疫相关性肾损伤3例的用药分析[J].药学与临床研究,2022,30(1):81~83 |
| PD-1/PD-L1抗体类药物致免疫相关性肾损伤3例的用药分析 |
| Three Cases of Immunorelated Nephritis Caused by PD-1/PD-L1 Antibody Drugs |
| 投稿时间：2021-04-16 修订日期：2022-02-14 |
| DOI： |
| 中文关键词: 程序性细胞死亡受体-1 程序性细胞死亡配体1 急性肾损伤 不良反应 |
| 英文关键词: Programmed cell death receptor-1 Programmed cell death ligand 1 Acute kidney injury Adverse reactions |
| 基金项目: |
|
| 摘要点击次数: 9466 |
| 全文下载次数: 7269 |
| 中文摘要: |
| 程序性细胞死亡受体1（PD-1）和程序性细胞死亡配体1（PD-L1）是免疫检查点抑制剂（ICIs）的主要靶点。为加强药学监护，降低ICIs不良反应的发生率，临床药师对3例肿瘤患者在应用注射用卡瑞利珠单抗、度伐利尤单抗、特瑞普利单抗后出现免疫相关性肾损伤的治疗过程及用药情况进行了研究分析。3个病例经过激素治疗后，肾功能均得到完全恢复。 |
| 英文摘要: |
| The main targets of immune checkpoint inhibitors (ICIs) are programmed cell death receptor-1 (PD-1) and programmed cell death ligand 1 (PD-L1). In order to strengthen pharmaceutical care and reduce incidence of adverse reactions caused by ICIs, clinical pharmacists studied and analyzed the treatment process and medication situation of immune-related renal injury in 3 tumor patients who had been treated with carrializumab, dovalizumab or triplizumab. In all three cases, renal function of the patients recovered completely after hormone therapy. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
